Search

Covalent and defect‐free surface‐grafted solid lubricating chains that can impart "liquid‐like" slippery behavior have proven advantageous over lubricant‐infused and textured anti‐wetting surfaces. Herein, the co‐hydrolysis and co‐condensation of a mixture of organosilanes followed by the epoxy‐amine ring opening reaction at the interface results in a highly robust, transparent, and "liquid‐like" solid slippery omniphobic coating (LL‐OSC). The presence of the epoxy‐terminated organosilane a) acts as a molecular spacer in between the low‐surface energy, rigid fluorine terminated silane and b) provides "reactive" epoxy groups for covalent binding to a pre‐functionalized amine surface for potential applicability in droplet transport and manipulation, diagnostics, etc. LL‐OSC exhibits resistance to both solid and liquid abrasions such as sandpaper abrasions, prolonged UV irradiation, DI water and high temperature (30 days), and submersion in chemically contaminated aqueous solutions. This is the first report of a hemocompatible solid slippery coating for inhibiting platelet adhesion, thus, paving way for blood‐contacting medical device applications. The LL‐OSC exhibits remarkable cytocompatibility, repellence to plasma protein, and cells and prevents biofilm formation. Additionally, the substrate‐independent LL‐OSC can be applied onto metals and polymers. This study envisions that the reported durable, solid slippery coating will find widespread applicability in hospital settings, electronic devices, etc. [ABSTRACT FROM AUTHOR]

The development of drug‐resistant microorganisms is taking a heavy toll on the biomedical world. Clinical infections are costly and becoming increasingly dangerous as bacteria that once responded to standard antibiotic treatment are developing resistance mechanisms that require innovative treatment strategies. Nitric oxide (NO) is a gaseous molecule produced endogenously that has shown potent antibacterial capabilities in numerous research studies. Its multimechanistic antibacterial methods prevent the development of resistance and have shown potential as an alternative to antibiotics. However, there has yet to be a direct comparison study evaluating the antibacterial properties of NO against antibiotic susceptible and antibiotic‐resistant clinically isolated bacterial strains. Herein, standardized lab and clinically isolated drug‐resistant bacterial strains are compared side‐by‐side for growth and viability following treatment with NO released from S‐nitrosoglutathione (GSNO), an NO donor molecule. Evaluation of growth kinetics revealed complete killing of E. coli lab and clinical strains at 17.5 mM GSNO, though 15 mM displayed >50% killing and significantly reduced metabolic activity, with greater dose dependence for membrane permeability. Clinical P. aeruginosa showed greater susceptibility to GSNO during growth curve studies, but metabolic activity and membrane permeability demonstrated similar effects for 12.5 mM GSNO treatment of lab and clinical strains. MRSA lab and clinical strains exhibited total killing at 17.5 mM treatment, though metabolic activity was decreased, and membrane permeation began at 12.5 mM for both strains. Lastly, both S. epidermidis strains were killed by 15 mM GSNO, with sensitivities in metabolic activity and membrane permeability at 12.5 mM GSNO. The mirrored antibacterial effects seen by the lab and clinical strains of two Gram‐negative and two Gram‐positive bacteria reveal the translational success of NO as an antibacterial therapy and potential alternative to standard antibiotic treatment. [ABSTRACT FROM AUTHOR]

Numerous biomaterials have been developed for application in blood‐contacting medical devices to prevent thrombosis; however, few materials have been applied to full‐scale devices and evaluated for hemocompatibility under clinical blood flow conditions. We applied a dual‐action slippery liquid‐infused (LI) nitric oxide (NO)‐releasing material modification (LINO) to full‐scale blood circulation tubing for extracorporeal lung support and evaluated the tubing ex vivo using swine whole blood circulated for 6 h at a clinically relevant flow. LINO tubing was compared to unmodified tubing (CTRL) and isolated LI and NO‐releasing modifications (n = 9/group). The primary objective was to evaluate safety and blood compatibility of this approach, prior to progression to in vivo testing of efficacy in animal models. The secondary objective was to evaluate coagulation outcomes relevant to hemocompatibility. No untoward effects of the coating, such as elevated methemoglobin fraction, were observed. Additionally, LINO delayed platelet loss until 6 h versus the reduction in platelet count in CTRL at 3 h. At 6 h, LINO significantly reduced the concentration of platelets in an activated P‐selectin expressing state versus CTRL (32 ± 1% decrease, p =.02). Blood clot deposition was significantly reduced on LINO blood pumps (p =.007) and numerically reduced on tubing versus CTRL. Following blood exposure, LINO tubing continued to produce a measurable NO‐flux (0.20 ± 0.06 × 10−10 mol cm−2 min−1). LINO is a potential solution to reduce circuit‐related bleeding and clotting during extracorporeal organ support, pending future extended testing in vivo using full‐scale extracorporeal lung support devices. [ABSTRACT FROM AUTHOR]